Sort
4,870 grants matching “glp 1”
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
$1,000,000Gail E Sonenshein · Adecto Pharmaceuticals, Inc. · R44 · FY2018 · CA
Novel Methods for Dissolving Blood Clots
$1,000,000Andrew H Kang · Translational Sciences, Inc. · R44 · FY2015 · HL
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
$1,000,000Thale Cross Jarvis · Crestone, Inc. · R44 · FY2014 · AI
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2015 · AI
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2023 · DK
Spectroscopic Localization of Breast Cancer
$999,999David A. Benaron · Spectros Corporation · R44 · FY2008 · CA
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2024 · DK
A new class of antibiotic to address Antimicrobial Resistance
$999,998Charles Testa · Curza Inc · R44 · FY2024 · AI
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$999,998Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2021 · CA
Development of the first HRV vaccine
$999,998Gregory John Tobin · Biological Mimetics, Inc. · R44 · FY2015 · AI
Development of the first HRV vaccine
$999,998Gregory John Tobin · Biological Mimetics, Inc. · R44 · FY2016 · AI
A novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), to treat resistant hypertension
$999,998Brian Laurence Johnson · Antlia Bioscience Inc · R44 · FY2024 · HL
Process development for manufacturing eCD4-Ig
$999,997Michael David Alpert · Emmune, Inc · R44 · FY2025 · AI
A new class of antibiotic to address Antimicrobial Resistance
$999,997Charles Testa · Curza Inc · R44 · FY2025 · AI
Reducing Stroke by a Novel, Clot-dissolving Antibody
$999,993Paul H Kussie · Translational Sciences, Inc. · U44 · FY2012 · NS
Reducing Stroke by a Novel, Clot-dissolving Antibody
$999,993Guy L Reed · Translational Sciences, Inc. · U44 · FY2014 · NS
CMC of Peptide Formulation for the Treatment of ARDS
$999,993Gerardo M. Castillo · Pharmain Corporation · R44 · FY2022 · HL
Reducing Stroke by a Novel, Clot-dissolving Antibody
$999,993Paul H Kussie · Translational Sciences, Inc. · U44 · FY2013 · NS
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
$999,982James G. Moe · Oligomerix, Inc · R44 · FY2019 · AG
Teixobactin Development for Anthrax
$999,978Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2020 · AI
Humanized monoclonal antibodies to treat mucormycosis
$999,975Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2024 · AI
Novel biologic to treat chemotherapy-induced neuropathic pain
$999,967Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2022 · CA
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
$999,937James G. Moe · Oligomerix, Inc · R44 · FY2020 · AG
Factor XII Inhibitor for Surface Initiated Thrombosis
$999,930Erik Ian Tucker · Aronora, Inc. · R44 · FY2020 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension
$999,898Lawrence S. Zisman · Pulmokine, Inc. · R44 · FY2015 · HL